Biotie's Stock Exchange Releases published in 2009
(Thomson Reuters ONE) -
BIOTIE THERAPIES CORP. STOCK EXCHANGE ANNOUNCEMENT 15 March 2010 at 1.10
p.m.
Biotie's Stock Exchange Releases published in 2009
The following list includes all Biotie Therapies Corp.'s Stock Exchange Releases
and Stock Exchange Announcements published in 2009.
Stock Exchange Releases, Stock Exchange Announcements and Press Releases
published by Biotie are available on the company's web site at
http://www.biotie.com/In_English/Investors/Stock_Exchange_Releases
February
03.02.2009
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
17.02.2009
Clinical study started with VAP-1 antibody in rheumatoid arthritis patients
March
12.03.2009
Nalmefene North-American rights acquired by Lundbeck
27.03.2009
Clinical study started with Biotie's proprietary VAP-1 antibody in psoriasis
patients
27.03.2009
Biotie Therapies Corp. Financial Statement Release January 1 - December 31, 2008
27.03.2009
Biotie's Annual Financial Report 2008 published
April
27.04.2009
Invitation to the Annual General Meeting of Biotie Therapies Corp.
27.04.2009
The Board of Directors of Biotie Therapies Corp. decided on the issuance of
option rights
27.04.2009
Biotie Therapies Corp. Annual Report 2008 published
May
15.05.2009
Biotie Therapies Corp. interim report January 1 - March 31, 2009
29.05.2009
Resolutions of the Annual General Meeting of Biotie Therapies Corp.
July
23.07.2009
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
August
07.08.2009
Biotie Therapies Corp. interim report January 1 - June 30, 2009
28.08.2009
Biotie reaches milestone in Wyeth collaboration
September
14.09.2009
Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353
22.09.2009
Biotie signs an LP market making agreement with Nordea
28.09.2009
Invitation to the Extraordinary General Meeting of Biotie Therapies Corp.
28.09.2009
Peter Fellner nominated to be elected to Biotie's Board of Directors
October
23.10.2009
Biotie secures committed standby equity up to 20 million Euro
23.10.2009
Biotie Therapies Corp. interim report January 1 - September 30, 2009
29.10.2009
Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp.
December
04.12.2009
Directed issue of new shares in Biotie Therapies Corp. to institutional
investors
07.12.2009
Biotie raises EUR 7.2 million - directed issue of new shares in Biotie Therapies
Corp. more than two times oversubscribed
08.12.2009
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
10.12.2009
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act
14.12.2009
New Biotie shares and increase of share capital registered with the trade
register
18.12.2009
Biotie´s financial information in 2010
18.12.2009
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act relating to decrease in holdings
Turku, March 15, 2010
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com
Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and
pre-clinical development. Biotie's products address diseases with high unmet
medical need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.
The commercial value of the pipeline has been demonstrated through existing
alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche
and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
For more information, please refer to www.biotie.com
[HUG#1393888]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2010 - 07:11 Uhr
Sprache: Deutsch
News-ID 1011385
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Turku
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 95 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie's Stock Exchange Releases published in 2009
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
